193 related articles for article (PubMed ID: 16730363)
1. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.
Mueller M; Ritmeijer K; Balasegaram M; Koummuki Y; Santana MR; Davidson R
Trans R Soc Trop Med Hyg; 2007 Jan; 101(1):19-24. PubMed ID: 16730363
[TBL] [Abstract][Full Text] [Related]
2. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
6. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E
J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541
[TBL] [Abstract][Full Text] [Related]
8. Ambisome plus miltefosine for Indian patients with kala-azar.
Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B therapy in kala-azar.
Giri OP
J Indian Med Assoc; 1993 Apr; 91(4):91-3. PubMed ID: 8409490
[TBL] [Abstract][Full Text] [Related]
10. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
[TBL] [Abstract][Full Text] [Related]
11. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
12. Comment on: Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.
de Górgolas M
Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):1054; author reply 1054-5. PubMed ID: 17651771
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
[TBL] [Abstract][Full Text] [Related]
14. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
15. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
16. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
[TBL] [Abstract][Full Text] [Related]
17. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
Ramesh V; Kumar J; Kumar D; Salotra P
Indian J Dermatol Venereol Leprol; 2010; 76(2):138-44. PubMed ID: 20228542
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
